Philippe Maitre, Executive Vice President, US Operations for Onxeo discusses Livatag, a nanoparticle formulation of doxorubicin (Transdrug technology) developed for the treatment of primary liver cancer.

Philippe Maitre, Executive Vice President, US Operations for Onxeo discusses Livatag, a nanoparticle formulation of doxorubicin (Transdrug technology) developed for the treatment of primary liver cancer.